CARMAT |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3.095 EUR | -22.53% |
|
-26.31% | -53.81% |
| May. 17 | Oddo BHF Cuts Carmat PT, Affirms Neutral Rating | MT |
| May. 17 | CARMAT : price target lowered by Oddo BHF | CF |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Hours!
Take advantage of the offer
* See conditions on site
| Sales 2023 | 2.8M 3.04M | Sales 2024 * | 14.85M 16.14M | Capitalization | 90.12M 97.94M |
|---|---|---|---|---|---|
| Net income 2023 | -53M -57.6M | Net income 2024 * | -38M -41.3M | EV / Sales 2023 | 59.2 x |
| Net Debt 2023 * | 49.63M 53.94M | Net Debt 2024 * | 61.25M 66.56M | EV / Sales 2024 * | 10.2 x |
| P/E ratio 2023 |
-3.09
x | P/E ratio 2024 * |
-2.27
x | Employees | 182 |
| Yield 2023 * |
-
| Yield 2024 * |
-
| Free-Float | 78.87% |
More Fundamentals
* Assessed data
More news
Latest transcript on CARMAT
More press releases
More news
| 1 day | -22.53% | ||
| 1 week | -26.31% | ||
| Current month | +2.82% | ||
| 1 month | -18.55% | ||
| 3 months | -29.26% | ||
| 6 months | -29.82% | ||
| Current year | -53.81% |
1 week
2.85
4.40
1 month
2.854.40
Current year
2.857.72
1 year
2.859.99
3 years
2.8531.70
5 years
2.8536.00
10 years
2.8596.00
| Managers | Title | Age | Since |
|---|---|---|---|
Stéphane Piat
CEO | Chief Executive Officer | - | 16-08-31 |
Alain Carpentier
FOU | Founder | 91 | 08-06-24 |
| Director of Finance/CFO | - | 18-12-11 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Alexandre Conroy
CHM | Chairman | 61 | 22-12-21 |
| Director/Board Member | 85 | 16-04-11 | |
Pierre Bastid
BRD | Director/Board Member | 69 | 18-04-04 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-17 | 3.095 | -22.53% | 1,368,371 |
| 24-05-16 | 3.995 | -2.08% | 47,518 |
| 24-05-15 | 4.08 | -2.86% | 47,207 |
| 24-05-14 | 4.2 | -1.18% | 82,696 |
| 24-05-13 | 4.25 | +1.19% | 68,180 |
Real-time Euronext Paris, May 17, 2024 at 11:36 am EDT
More quotes
CARMAT specializes in the development of a fully implantable orthotopic artificial heart, its electrical power supply system, and its telediagnostics system. The artificial heart is intended for patients with advanced cardiac insufficiency who are ineligible for a transplant and have exhausted all medication alternatives.
Calendar
2024-05-29
- Annual General Meeting
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
3.095
EUR
Average target price
12.98
EUR
Spread / Average Target
+319.22%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -53.81% | 97.98M | |
| -5.10% | 11.34B | |
| +4.02% | 9.11B | |
| +38.12% | 5.53B | |
| -23.70% | 4.61B | |
| +8.55% | 3.45B | |
| -6.44% | 2.87B | |
| -5.85% | 2.1B | |
| -11.84% | 2.08B | |
| -23.36% | 1.78B |
- Stock Market
- Equities
- ALCAR Stock
